Tag: FDA

Melanoma Treatments: Breakthroughs for Multiple Cancers — for Real and Right Now

By Louise M. Perkins, Ph.D., MRA Chief Science Officer | 10 July 2017 In Science, Treatment

While 2014 and 2015 offered a whirlwind of good news related to new melanoma treatments from immune to targeted therapy, since then, it’s been a bit quieter in melanoma. Although there has been exceptional news in regard to other cancers. Why is that, and what are the latest breakthroughs?

Read More


Sunscreen Laws may Hinder Protecting Children from Exposure

By Pamela Goldsmith, MRA Director of Communications | 10 July 2017 In News, Policy, Prevention

With the launch of summer comes conventional discussion around ranking sunscreens, and chatter between the experts to parse what should be considered in choosing the most effective among them. It’s also a key conversation among parents heading into the season with an eye on protecting their children from sun exposure. Yet, something remaining a central concern among those parents is the public policy surrounding use of sunscreen in schools.

Read More


Strides and Obstacles in Melanoma Research Spotlight on Martin McMahon, PhD

By Pamela Goldsmith, MRA Director of Communications | 6 June 2017 In Science, Treatment

Like so many in the melanoma research field, Martin McMahon, PhD, Huntsman Cancer Institute’s senior director of pre-clinical translation and Professor at the University of Utah, entered the melanoma field by accident.

Read More


Melanoma Prevention: The Latest Advances & Future Directions

By Pamela Goldsmith, MRA Director of Communications | 28 February 2017 In Events, Policy, Prevention, Science

During my interview with Susan Swetter, MD, Professor of Dermatology,
Stanford University and VA Palo Alto, at the Melanoma Research Alliance Ninth Annual Scientific Retreat in Washington, DC, I inquired about the Panel Discussion she was part of titled: News from the field: What’s going well and what remains to be done?

Read More


8th Annual Scientific Retreat Recap

7 March 2016 In Events, Science

The end of February was a momentous one for the MRA team and all the folks in the melanoma community. We hosted our 8th Annual Scientific Retreat in Washington, DC, and they truly just seem to get better and better. The Retreat serves two main roles for those invited participants.

Read More


Expanded Access Programs: A Time of Amazement in Melanoma

By Louise M. Perkins, Ph.D., MRA Chief Science Officer | 28 August 2014 In Science, Treatment

For those of you keeping a close eye on the field of melanoma treatments, you know that we find ourselves living in a simply amazing period of opportunity and innovation—even though there is still a long way to go.

Read More



The First FDA Approval of Two Melanoma Therapies in Combination

By Louise M. Perkins, Ph.D., MRA Chief Science Officer | 10 January 2014 In News

You may have heard this from other sources already, but we want to take a minute and explain why we’re so excited at MRA by some recent news. This week, GlaxoSmithKline announced that it had received approval from the U.S. Food and Drug Administration (FDA) of a combination treatment for melanoma.

Read More


Looking Back on 2013

23 December 2013 In News

From everyone here at the Melanoma Research Alliance (MRA), we wish you a healthy and happy holiday season and extend our heartfelt gratitude for an amazing year of progress and collaboration. We are so thankful for the tremendous support we received this year from so many people who share our...

Read More


New Melanoma Therapies Approved

31 May 2013 In News

These are the best types of posts to write:  On Wednesday, the US Food and Drug Administration (FDA) approved two genetically-targeted melanoma therapies as well as a companion diagnostic test that will be used to determine which patients' tumors carry the specific genetic mutations the treatments target.

Read More

Login

×